Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002453 (amenorrhea)
 6,245 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

18 pregnancies occurred after treatment with bromoergocryptine in 17 patients who wished to conceive, but who suffered from anovulation of varying aetiology. The course of 15 pregnancies was uneventful. Three pregnancies ended in abortion. Nine of the 17 women had hyperprolactinemic amenorrhea. Furthermore, one woman had normoprolactinemic post-pill amenorrhea, another normoprolactinemic anovulatory oligomenorrhea and a third normoprolactinemic anovulatory regular menstruations. With the exception of one woman, all had galactorrhea. The courses of pregnancy were monitored by frequent ultrasound measurements of the fetal biparietal diameter, maternal urinary estriol excretion and radioimmunological measurements of plasma estrone, estradiol, unconjugated and immunoreactive estriol, progesterone, and HPL. All data were within the normal ranges and all babies were healthy at birth and had no teratogenic defects. The data prove the great value of bromoergocryptine in the treatment of hyperprolactinemic anovulation, sometimes even in the treatment of normoprolactinemic anovulation. Moreover, the results indicate no adverse effect on either the course or the outcome of pregnancy.
 ...
PMID:Intrauterine development, feto-placental function and pregnancy outcome after induction of ovulation with bromoergocryptine. 58 Jul 7

E3 and HPL hormone levels in maternal plasma are predictable of adequate birth weight for gestation age (AGA) when their values are higher than the mean for the term of pregnancy, but low values correspond to 'small-for-gestation-age' (SGA) infants in about 50% of the cases only. DHA-S (50 mg i.v.) half-life (DHS-S t 1/2) was calculated by least-squares analysis on the plot of log DHA-S concentration versus time at several intervals. 102 tests were performed in pregnant women between 30 and 41 weeks of amenorrhea (43 control, 59 suspicion of IUGR among them 29 AGA and 20 SGA). The difference between DHA-S t 1/2 is statistically highly significant (p < 0.001) between SGA and the other groups. Evaluation of birth weight was correct in 95 cases (76 normal babies < 4.29 h, and 19 SGA greater than or equal to 4.29 h, showed false-positive results in 6 cases, and false-negative in 1 case. This test has now been included in our routine practice for further evaluation of intrauterine growth retardation.
 ...
PMID:Exogenous DHA-S half-life: a good index of intrauterine growth retardation. 743 10